Vor Biopharma Inc (VOR)

$37.46 +0.78 (2.13%)
Market Cap 256.75M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 390,900
Avg Vol 313,340
Day's Range N/A - N/A
Shares Out 6.85M
Stochastic %K 46%
Beta 2.07
Analysts Sell
Price Target $35.75

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
Vikingsstrade
Vikingsstrade Oct. 3 at 5:33 PM
$VOR $BIAF $ECDA $ATHA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Khaled43
Khaled43 Oct. 3 at 2:19 PM
$BIAF $ECDA $SQNS $VOR Ecda
0 · Reply
Super_Kelsey
Super_Kelsey Oct. 3 at 2:07 AM
Looks like all eyes will be on ticker GIPR tomorrow. GIPR is the type of tickers market sending up on a massive 200-300%+ rally. Don't miss it be early bulls. $VOR $AIRE $FAAS $SONM
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 2 at 11:45 PM
$VOR $BIAF $ECDA $SQNS !!
0 · Reply
MTRADe_01
MTRADe_01 Oct. 2 at 7:17 PM
$KAVL scalp only >0.69, dilution risk otherwise $VOR avoid unless news drops $FRMI IPO hype — only entry if >IPO high with volume $MTEN pure spec, only chase halts-up trend Follow along for the best squeeze setups every day 🚨
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:17 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $BINI $VOR $BIAF $ECDA 🔥
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 4:39 PM
Top Gainers PT2 $DPRO $ANAB $VOR $AIIO $FATE
0 · Reply
SnoopDawg
SnoopDawg Sep. 30 at 4:30 PM
$VOR usually Chinese approvals dont drive biotechs.
1 · Reply
stonebread
stonebread Sep. 30 at 4:07 PM
$VOR too much mental pressure and exited at $33. Gl guys.
0 · Reply
OrionCrestCapital
OrionCrestCapital Sep. 30 at 3:52 PM
$VOR Enterprise logos beyond Amazon validate service and NXXT should add 2 or 3 national accounts as utilization and reliability improve.
0 · Reply
Latest News on VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:01 PM EDT - 1 day ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 29, 2025, 7:00 AM EDT - 5 days ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Sep 25, 2025, 11:48 AM EDT - 9 days ago

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 23, 2025, 8:00 AM EDT - 11 days ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 9:00 PM EDT - 17 days ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 17, 2025, 4:15 PM EDT - 17 days ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 12, 2025, 4:15 PM EDT - 22 days ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Vor Bio to Participate in Upcoming Investor Conferences

Aug 26, 2025, 8:00 AM EDT - 5 weeks ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 11:15 AM EDT - 7 weeks ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 7 weeks ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 2 months ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 2 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 2 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 3 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 3 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 3 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 3 months ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 3 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 5 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 8 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 8 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 9 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 10 months ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 10 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 9, 2023, 4:01 PM EST - 2 years ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 7, 2023, 4:05 PM EST - 2 years ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Nov 2, 2023, 9:01 AM EDT - 2 years ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

Jul 5, 2023, 8:51 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 9, 2023, 7:30 AM EDT - 2 years ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Vikingsstrade
Vikingsstrade Oct. 3 at 5:33 PM
$VOR $BIAF $ECDA $ATHA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Khaled43
Khaled43 Oct. 3 at 2:19 PM
$BIAF $ECDA $SQNS $VOR Ecda
0 · Reply
Super_Kelsey
Super_Kelsey Oct. 3 at 2:07 AM
Looks like all eyes will be on ticker GIPR tomorrow. GIPR is the type of tickers market sending up on a massive 200-300%+ rally. Don't miss it be early bulls. $VOR $AIRE $FAAS $SONM
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 2 at 11:45 PM
$VOR $BIAF $ECDA $SQNS !!
0 · Reply
MTRADe_01
MTRADe_01 Oct. 2 at 7:17 PM
$KAVL scalp only >0.69, dilution risk otherwise $VOR avoid unless news drops $FRMI IPO hype — only entry if >IPO high with volume $MTEN pure spec, only chase halts-up trend Follow along for the best squeeze setups every day 🚨
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:17 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $BINI $VOR $BIAF $ECDA 🔥
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 4:39 PM
Top Gainers PT2 $DPRO $ANAB $VOR $AIIO $FATE
0 · Reply
SnoopDawg
SnoopDawg Sep. 30 at 4:30 PM
$VOR usually Chinese approvals dont drive biotechs.
1 · Reply
stonebread
stonebread Sep. 30 at 4:07 PM
$VOR too much mental pressure and exited at $33. Gl guys.
0 · Reply
OrionCrestCapital
OrionCrestCapital Sep. 30 at 3:52 PM
$VOR Enterprise logos beyond Amazon validate service and NXXT should add 2 or 3 national accounts as utilization and reliability improve.
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 3:14 PM
$VOR heating up…
0 · Reply
YakoCapital
YakoCapital Sep. 30 at 3:01 PM
$VOR Great CEO, great product! 👍
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:57 PM
$VOR Vor Biopharma: 43 trades, $13.6K vs $285K avg (0.05x). $12.4K calls / $0.001K puts. $BLND Blend Labs: 49 trades, $12.7K vs $141K avg (0.09x). $12.4K calls / $0.3K puts. $ASTX Tradr 2X Long $ASTS ETF: 21 trades, $16.8K vs $63K avg (0.26x). $12.4K calls / $4.3K puts. $ACAD Acadia Pharma: 92 trades, $16.7K vs $114K avg (0.15x). $12.4K calls / $4.3K puts.
0 · Reply
nubewithcash
nubewithcash Sep. 29 at 10:37 PM
$VOR This stock reminds me of a venomous Spider. "I'm not touching that". Got out before the reverse split. which would have turned my 3,000 shares into 150. What type of shenanigans are going on with these crazy valuations. why doesn't the chart show that this was trading at .16 this summer?
0 · Reply
YakoCapital
YakoCapital Sep. 29 at 5:57 PM
$VOR $100 is coming!
0 · Reply
chickenwingww
chickenwingww Sep. 29 at 1:51 PM
$VOR Effect likely any day on $VOR, stock will be crushed.
0 · Reply
chickenwingww
chickenwingww Sep. 29 at 1:50 PM
$VOR (b) the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Initial Registration Statement will not be “reviewed” or will not be subject to further review
0 · Reply
Lohengrin72
Lohengrin72 Sep. 29 at 1:05 PM
$VOR @Natha_ ouch!
1 · Reply
OpenOutcrier
OpenOutcrier Sep. 29 at 12:30 PM
$VOR (+2.9% pre) Major Autoimmune Breakthrough: Vor Bio's Phase 3 Sjögren's Disease Trial Results Set for ACR 2025 Reveal https://ooc.bz/l/78701
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 11:10 AM
$VOR 07:07 on Sep. 29 2025 Vor Bio Announces Phase 3 Telitacicept Data In Primary Sjögren's Disease To Be Presented At ACR Convergence 2025 #tradeideas
0 · Reply
Lohengrin72
Lohengrin72 Sep. 27 at 8:20 AM
$VOR to the shorts waiting for dilution: Do you guys understand the "dilution blocker" of the warrants? Here AI about the Venrock filing: "Despite holding warrants for nearly 5 million shares, the Beneficial Ownership Blocker limits the Reporting Persons from exercising them beyond a threshold: Ownership cap: 9.99% of the Issuer’s outstanding common stock. Current exercise limit: 760,699 shares total across all entities. This means they can only exercise a portion of their warrants to stay under the 9.99% cap, regardless of how many they technically hold." No one can convert the warrants without the other holders because the share of the company would be quickly above 9.99%. Until they all convert together: low float and possible transformative news on the horizon. Be careful.
2 · Reply
SMARTR8
SMARTR8 Sep. 25 at 2:21 PM
$VOR $OPEN $CTMX $TLRY $NIO BANGER AFTER BANGER. View pinned on profile or simply join the FREE discord ⬇️🤝👀😎✅️✅️✅️✅️🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑✅️
0 · Reply